摘要
目的 :建立一种检测血清Her 2 /neu的快速、简单的方法 ,并从临床的角度探讨了血清Her 2 /neu与组织Her 2 /neu表达及其他因素的相关性。方法 :收集初治乳腺癌 5 3例 ,采用ELISA方法检测血清Her 2 /neu水平 ,并采用免疫组化方法对术后标本进行组织Her 2 /neu表达的检测 ;同时设立了 10例正常人、31例乳腺良性病变为对照。结果 :早期乳腺癌中 ,10 / 5 3(19% )血清Her 2 /neu水平高于正常 ,组织Her 2 /neu表达阳性者中 32 %血清Her 2 /neu阳性 ,而组织表达阴性者中仅7%血清阳性 ,二者有相关性 (P <0 0 5 )。血清Her 2 /neu水平与肿瘤大小有相关性 (P <0 5 ) ,与淋巴结、受体状况无关。结论 :血清Her 2 /neu与组织Her 2 /neu有一致性 ,前者可作为后者的补充。
Objective:To establish a method to detect the level of serum Her-2/neu and study the relationship between serum Her-2/neu level and tissue Her-2/neu overexpression and other factors. Methods:A total of 120 females were included in the study which including 10 normal controls, 31 benign breast disease patients and 53 primary breast cancer. The level of serum Her-2/neu was detected with the method of ELISA. The Her-2/neu overexpression of the primary tumor of breast cancer was measured by the IHC.Results:We observed elevated serum Her-2/neu levels in 10/53(19%) preoperative patients. In 32% of the patients with Her-2/neu tumor expression serum levels were increased. In contrast, only 7% of the patients without Her-2/neu expression in the primary tumor presented with elevated serum levels. There was a correlation between serum concentrations of soluble Her-2/neu and tumor size(P<0.05), there was no correlation between serum concentration and axillary lymph node or estrogen (P>0.05). Conclusion:There is a correlation between serum Her-2/neu levels and tissue Her-2/neu overexpression, serum Her-2/neu may have relationship with tumor loads of breast cancer.
出处
《临床肿瘤学杂志》
CAS
2004年第5期449-451,共3页
Chinese Clinical Oncology
基金
国家"十.五"攻关课题 (2 0 0 1BA 70 5B10 - 3)
